The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Multi-omics analysis of human kidney PDGFRβ+ mesenchymal cells quantified over 14,000 biomolecules across 8 time points, ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

Patients with diabetic kidney disease (DKD) and anemia have no worse, and possibly better, cardiovascular outcomes from finerenone treatment.

A major international study presented at the 62nd ERA Congress reveals that the long-accepted survival advantage of ...